Get the Stockscreener App
4.77
6.24%
0.28
After Hours:
4.77
Whitehawk Therapeutics Inc stock is traded at $4.77, with a volume of 1.01M.
It is up +6.24% in the last 24 hours and up +18.36% over the past month.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
See More
Previous Close:
$4.49
Open:
$4.5
24h Volume:
1.01M
Relative Volume:
3.51
Market Cap:
$235.89M
Revenue:
$7.15M
Net Income/Loss:
$-20.60M
P/E Ratio:
10.05
EPS:
0.4746
Net Cash Flow:
$-97.99M
1W Performance:
+17.20%
1M Performance:
+18.36%
6M Performance:
+107.39%
1Y Performance:
+171.02%
1-Day Range:
$4.50
$5.21
1-Week Range:
$3.97
$5.21
52-Week Range:
$1.57
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
4.77 | 222.04M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Oppenheimer | Outperform |
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesTrade Idea Marketplace - Newser
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for CPT113 Linker-Payload Technology and Advances Clinical Programs - Minichart
Whitehawk expands ADC pipeline with Hangzhou DAC option deal - Investing.com UK
Whitehawk Expands CPT113 ADC Platform Through New Option Deal - TipRanks
Whitehawk Therapeutics expands ADC pipeline with option for CPT113 across up to five programs - TradingView
Whitehawk Therapeutics (WHWK) Climbs +3.69% — Resistance at $4.43 in Focus 2026-05-20Option Breadth - Newser
Cancer treatment developer Whitehawk joins TD Cowen oncology summit - Stock Titan
Acuta Capital boosts Whitehawk (WHWK) stake to about 9% after PIPE - Stock Titan
Whitehawk Therapeutics (WHWK) CMO receives 19,132-share stock grant at $3.92 - Stock Titan
Whitehawk Therapeutics (WHWK) executive awarded 51,020 shares in Form 4 filing - Stock Titan
Whitehawk Therapeutics (WHWK) CFO receives 38,265-share stock award - Stock Titan
Whitehawk Therapeutics (WHWK) CEO awarded 51,021 shares in new stock grant - Stock Titan
Whitehawk Therapeutics (WHWK) director gains stock grant and large pre-funded warrant - Stock Titan
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - marketscreener.com
WHWK PE Ratio & Valuation, Is WHWK Overvalued - Intellectia AI
WHWK SEC FilingsWhitehawk Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Whitehawk Therapeutics, Inc.Common Stock (NQ: WHWK - The Chronicle-Journal
Whitehawk Therapeutics: 'Hold' On Name Change, Next Generation PTK7 ADC Targeting (WHWK) - Seeking Alpha
Avoro boosts Whitehawk Therapeutics (WHWK) stake with pre-funded PIPE warrants - Stock Titan
Avoro Capital Advisors boosts Whitehawk (NASDAQ: WHWK) stake with 6.38M pre-funded warrants - Stock Titan
JonesTrading Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $7 - Moomoo
May 2026's Promising Penny Stocks - simplywall.st
Wilson Sonsini Advises Whitehawk Therapeutics on $87.5 Million PIPE Financing - Wilson Sonsini
Whitehawk Therapeutics Raises $87.5M in Private Placement to Advance Antibody Drug Conjugate Cancer Pipeline - Minichart
Whitehawk Therapeutics announces $87.5m private placement equity financing - marketscreener.com
Whitehawk Therapeutics raises $87.5m in private placement By Investing.com - Investing.com Australia
Whitehawk Therapeutics Raises $87.5M PIPE Financing to Advance ADC Cancer Pipeline - citybiz
Whitehawk Therapeutics Announces $87.5 Million PIPE Financing - TipRanks
Whitehawk Therapeutics raises $87.5m in private placement - Investing.com
Whitehawk Therapeutics Raises $87.5 Million in PIPE, Selling Stock and Pre-Funded Warrants - TradingView
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing - TradingView
Whitehawk (Nasdaq: WHWK) prices $87.5M PIPE to fund ADC pipeline - Stock Titan
Number of shareholders of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Number of shareholders of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
Whitehawk Therapeutics, Inc. announced that it expects to receive $87.499998 million in funding from Coastlands Capital LP, QVT Financial LP, Avoro Capital Advisors LLC, Invus Financial Advisors, LLC, The Invus Group, LLC - marketscreener.com
Natural gas mineral firm WhiteHawk reveals sevenfold revenue surge in US IPO filing - Reuters
Whitehawk Therapeutics stock rating reaffirmed at Citizens on ADC progress By Investing.com - Investing.com Canada
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Oppenheimer Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Whitehawk Therapeutics (NASDAQ: WHWK) posts Q1 2026 loss as ADC focus ramps - Stock Titan
Whitehawk (Nasdaq: WHWK) posts Q1 loss with cash runway into 2028 - Stock Titan
WHITEHAWK THERAPEUTICS ($WHWK) Releases Q1 2026 Earnings - Quiver Quantitative
Whitehawk Therapeutics Q1 net loss beats estimates - TradingView
Cancer drug developer Whitehawk says $123M can fund operations into 2028 - Stock Titan
The sustainable advantages Whitehawk Therapeutics (WHWK) is developing (Eye on Rally) 2026-05-05Social Flow Trades - newser.com
Whitehawk Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Whitehawk Therapeutics (WHWK) price target increased by 10.29% to 6.38 - MSN
WHWK Whitehawk Therapeutics reports far wider than expected Q4 2025 loss, with shares edging 0.5% lower today.Revenue Breakdown Analysis - Newser
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Whitehawk Therapeutics Inc Stock (WHWK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER |
Apr 15 '26 |
Sale |
3.86 |
77,000 |
297,220 |
436,824 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):